We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+5.16%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
+$66.6M
Cap. Flow
+$201M
Cap. Flow %
50.06%
Top 10 Hldgs %
50.8%
Holding
80
New
26
Increased
21
Reduced
6
Closed
26

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$19.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$15.5M
3
NUVL
Nuvalent
NUVL
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$12.7M
5
ALKS icon
Alkermes
ALKS
+$10.6M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$15.8M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$14M
3
APLT
Applied Therapeutics
APLT
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$9.5M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$7.06M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
26
Protagonist Therapeutics
PTGX
$9.06B
$5.47M 1.37%
+141,714
New +$6.18M
SLRN
27
DELISTED
ACELYRIN
SLRN
$5.35M 1.34%
1,704,825
+386,971
+29% +$1.87M
SRZN icon
28
Surrozen
SRZN
$255M
$5.03M 1.26%
350,573
+167,655
+92% +$1.78M
MLYS icon
29
Mineralys Therapeutics
MLYS
$2.39B
$4.93M 1.23%
+400,101
New +$5.23M
NMRA icon
30
Neumora Therapeutics
NMRA
$298M
$4.54M 1.13%
+428,137
New +$5.13M
EYPT icon
31
EyePoint Inc
EYPT
$1.12B
$4.32M 1.08%
+579,500
New +$5.39M
RARE icon
32
Ultragenyx Pharmaceutical
RARE
$2.88B
$4.28M 1.07%
+101,809
New +$5.05M
ETNB
33
DELISTED
89bio
ETNB
$4.27M 1.07%
+545,800
New +$4.49M
CYTK icon
34
Cytokinetics
CYTK
$10.9B
$3.93M 0.98%
83,576
+69,112
+478% +$3.59M
CTNM
35
Contineum Therapeutics
CTNM
$532M
$3.89M 0.97%
+265,833
New +$4.21M
EWTX icon
36
Edgewise Therapeutics
EWTX
$4.28B
$3.54M 0.88%
132,706
+112,806
+567% +$3.59M
RCKT icon
37
Rocket Pharmaceuticals
RCKT
$376M
$3.41M 0.85%
+270,983
New +$4.08M
JSPR icon
38
Jasper Therapeutics
JSPR
$24.8M
$2.89M 0.72%
+135,244
New +$2.82M
TRML
39
DELISTED
Tourmaline Bio
TRML
$2.56M 0.64%
126,400
+70,877
+128% +$1.78M
ELVN icon
40
Enliven Therapeutics
ELVN
$3.8B
$2.18M 0.54%
+96,716
New +$2.51M
BBOT
41
BridgeBio Oncology
BBOT
$686M
$2.11M 0.53%
200,900
+900
+0.5% +$9.47K
TARA icon
42
Protara Therapeutics
TARA
$230M
$1.76M 0.44%
332,394
-610,463
-65% -$1.97M
QURE icon
43
uniQure
QURE
$2.77B
$1.59M 0.4%
+90,000
New +$777K
PCSC
44
Perceptive Capital Solutions
PCSC
$123M
$1.53M 0.38%
150,000
– –
VRNA
45
DELISTED
Verona Pharma
VRNA
$1.31M 0.33%
+28,136
New +$1.06M
CDTX
46
DELISTED
Cidara Therapeutics
CDTX
$1.28M 0.32%
+47,642
New +$774K
ATYR
47
aTyr Pharma
ATYR
$50M
$726K 0.18%
+200,475
New +$607K
ARQT icon
48
CALL
Arcutis Biotherapeutics
ARQT
$3.56B
$581K 0.14%
1,575,000
+1,325,000
+530% +$14.5M
QQQ icon
49
PUT
Invesco QQQ Trust
QQQ
$466B
$515K 0.13%
+70,000
New +$35.4M
TECX
50
Tectonic Therapeutic
TECX
$615M
$436K 0.11%
+9,434
New +$399K
1
2
3 4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Stempoint Capital held 80 positions worth $401M, up 20% from $334M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $201M of net new capital in Q4 2024, opening 26 new positions and adding to 21 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $14M trimmed.

  • Stempoint Capital's largest Q4 2024 buy was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.
  • Stempoint Capital added most to Syndax Pharmaceuticals in Q4 2024, an estimated $19.5M increase.
  • Stempoint Capital's biggest Q4 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $14M.
  • Stempoint Capital fully exited Amicus Therapeutics in Q4 2024, selling an estimated $15.8M.
  • Stempoint Capital's ten largest holdings make up 51% of its $401M portfolio in Q4 2024.
  • Stempoint Capital opened 26 new positions and closed 26 in Q4 2024.
  • Stempoint Capital's portfolio value rose 20% quarter-over-quarter to $401M.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.